Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: GlobeNewswire
License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional proteinPlan to initiate placebo-controlled study of AXO-AAV-OPMD in patients with oculopharyngeal muscular dystrophy (OPMD) in 2019License also grants rights to five additional investigational gene therapy products for neurological conditionsNew agreement further demonstrates Axovant’s commitment to the development and commercialization of transformational therapies for neurological diseasesConference call / webcast to be held July 9, 2018 at 8:30am EDT BASEL, Switzerland, July 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaborati
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $400.00 price target on the stock.MarketBeat
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safety [Yahoo! Finance]Yahoo! Finance
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safetyPR Newswire
- Axon Enterprise (AXON) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 4/19/24 - Form POSASR
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEFA14A
- AXON's page on the SEC website